Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 4, 2021 7:01 AM ESTCompany on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021Â
 On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021
 Company to discontinue Phase 3 COVID-19 trial (LOSVID)Â
Extended cash runway into 4Q 2022; raised $50.6 million in gross proceeds from January 2021 public offering
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., March 04,... More
